The AP3D1 Knouckout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT-29 colorectal adenocarcinoma line, generated to disrupt the AP3D1 gene. This heterogeneous pool contains a variety of loss-of-function alleles, providing a robust model system while avoiding the clonal selection biases inherent in single-cell-derived knockouts. The polyclonal nature maintains genetic diversity and allows for rapid functional genomics studies in an epithelial cancer context.
The parental HT-29 cell line was established from a primary colorectal adenocarcinoma of a 44-year-old female and exhibits adherent epithelial morphology. HT-29 cells are a cornerstone model in cancer research, widely employed to study intestinal epithelial biology, tumor progression, and drug sensitivity. Their well-documented genomic profile and ease of culture make them a reliable host for targeted gene disruption.
AP3D1 encodes the delta subunit of the adaptor protein complex-3 (AP-3), a heterotetramer that together with AP3B1, AP3M1, and AP3S1 orchestrates vesicular trafficking from the trans-Golgi network to lysosomes and related organelles. AP-3 recognizes tyrosine-based and dileucine sorting motifs on cargo molecules such as LAMP1, LAMP2, CD63, and tyrosinase, and partners with clathrin heavy chain and the small GTPase ARF1 to form transport vesicles. AP3D1 expression is under the transcriptional control of TFEB and MITF, upstream regulators that integrate nutrient and stress signals via mTORC1. Downstream consequences of AP3D1 disruption include missorting of lysosomal membrane proteins, defective autophagy as evidenced by accumulation of SQSTM1/p62, and impaired lysosomal biogenesis.
In the context of HT-29 colorectal cancer cells, AP3D1 knockout allows dissection of the interplay between endolysosomal trafficking and oncogenic processes. Loss of AP-3 function compromises lysosomal integrity and autophagy, which may influence tumor cell survival, metabolic adaptation, and response to chemotherapy. This model provides a physiologically relevant platform to explore how defects in cargo sorting contribute to colorectal cancer pathogenesis and could inform strategies for targeting lysosomal pathways in cancer therapy.
These polyclonal knockout cells are suited for diverse experimental applications, including mechanistic studies of Hermansky-Pudlak syndrome type 2, analysis of lysosomal storage disorders, and characterization of autophagic flux. Standard assays such as Western blotting for LAMP1 and p62, immunofluorescence staining of cathepsin D, flow cytometric measurement of surface CD63, and LC3-I/II conversion assays can be readily employed. The model also supports cancer biology research, including drug delivery and migration studies. For additional product details, please contact Ascent Research.
